For lung cancer, patients with EFGR+ status (n = 367) showed an mOS of 24.9 months (95% CI: 23.9–25.3) with a 33.6% reduction in the risk of mortality compared to those with EGFR-status (n = 467). This evidence concerns the gene EGFR and lung cancer.